Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden
Helicobacter · 2024
DOI: 10.1111/hel.70001 ↗At a glance
Kohortenstudie in Helicobacter, 2024. Written by Qing Liu and 4 co-authors. Institution: Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Colorectal Neoplasms, Helicobacter Infections, Helicobacter pylori. Cited 19 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: China Scholarship Council, Vetenskapsrådet.
Abstract (original language)
Background
Helicobacter pylori ( H. pylori ) is an established gastric carcinogen, also associated with an increased risk of colorectal cancer. Therefore, we suspected that H. pylori eradication lowers the risk of colorectal cancer. Material and Methods We assessed if H. pylori eradication therapy is associated with a reduced risk of colorectal adenocarcinoma in a population‐based nationwide cohort study. This study included all Swedish adults with at least one recorded H. pylori eradication episode between July 2005 and December 2012, based on the high‐quality Swedish health registries. Colorectal adenocarcinoma risks were compared to the Swedish background population, presented as standardized incidence ratios (SIRs) and 95% confidence intervals (CIs), accounting for age, sex, calendar period, tumor location (left or right sided), stage, and number of eradication episodes, from 1 year after eradication and onward.
Results
Among 80,381 individuals receiving H. pylori eradication therapy (average follow‐up 4.1 years), 282 were diagnosed with colorectal cancer (97.2% adenocarcinoma). Overall, H. pylori eradication was associated with an elevated risk of colorectal adenocarcinoma (SIR 1.27, 95% CI: 1.12–1.43). The colorectal adenocarcinoma risk was increased 1–2 years after eradication (SIR 1.42, 95% CI: 1.17–1.72), then decreased 2–4 years (SIR 0.80, 95% CI: 0.65–0.98) and 4–6 years (SIR 0.76, 95% CI: 0.57–0.99), yet not ≥ 6 years (SIR 1.36, 95% CI: 0.78–2.21) after eradication compared to the general population. Overall, right‐sided (SIR 1.47, 95% CI: 1.21–1.76) and left‐sided (SIR 1.35, 95% CI: 1.09–1.67) colon adenocarcinomas risks were higher among eradicated individuals than the general population.
Conclusion
H. pylori eradication was not associated with a clear and consistent reduction of colorectal cancer in our Swedish cohort.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
- Department of Surgery, Capio Saint Göran Hospital, Stockholm, Sweden.
- Clinical Epidemiology and Biostatistics School of Medical Sciences, Örebro University, Örebro, Sweden.
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- Global Health Institute, University of Antwerp, Antwerp, Belgium.
ORCID profiles: Lars Engstrand, Nele Brusselaers
Funding
- China Scholarship Council
- Vetenskapsrådet
Cite
APA
Liu, Q., Sadr-Azodi, O., Engstrand, L., Fall, K., & Brusselaers, N. (2024). Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden. Helicobacter. https://doi.org/10.1111/hel.70001
Vancouver
Liu Q, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden. Helicobacter. 2024. doi:10.1111/hel.70001
BibTeX
@article{Liu2024,
author = {Liu, Qing and Sadr-Azodi, Omid and Engstrand, Lars and Fall, Katja and Brusselaers, Nele},
title = {Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.70001}
}
EUVIMED